# Exploring the Role of Tesamorelin in Cardiovascular Health Among HIV Patients

Canonical source: https://retacompare.com/research/exploring-the-role-of-tesamorelin-in-cardiovascular-health-among-hiv-patients

Growth Hormone Peptides · 2026-01-01


    Tesamorelin has demonstrated potential in mitigating cardiac effects linked to antiretroviral therapy. The introduction of combination antiretroviral therapy (cART) has significantly improved survival rates among individuals with HIV, yet it has also led to an increase in age-associated comorbidities, particularly cardiovascular diseases (CVD). This study investigates how different dietary compositions interact with cART regimens and their effects on electrocardiographic parameters and myocardial histopathology.

 What this study examined

This research involved a total of 120 weanling Sprague Dawley rats, which were divided into three dietary groups: normal chow, a calorie-dense low protein (CDLP) diet, and a calorie-dense normal protein (CDNP) diet. Each dietary group was further subdivided into four treatment groups over a 9-week period, including a control group receiving normal saline, a test group receiving dolutegravir (DTG) plus tesamorelin, a DTG-only group, and a positive control group receiving a classical cART regimen. The study aimed to assess the impact of these diets and treatments on ECG recordings and myocardial histopathology at the end of the 24-week period.

 Why it matters for Tesamorelin research

The findings from this study are particularly relevant for understanding the role of Tesamorelin in cardiovascular health among individuals undergoing cART. As the prevalence of CVD increases in the HIV population, identifying therapeutic agents that can mitigate these risks is critical. Tesamorelin's ability to prevent deleterious cardiac effects associated with DTG-based and classical cART regimens suggests a protective role that warrants further investigation in clinical settings.

 Key findings

Significant intergroup variations in ECG indices were observed, including Q, R, S, and T wave amplitudes, PR interval, QRS duration, ST height, and QTc.

Myocardial fibrosis was evident in the DTG-only and classical cART groups maintained on both CDLP and CDNP diets.

Tesamorelin appeared to prevent the adverse cardiac effects induced by the combination of dietary regimens and cART.

The study highlighted the potential dysfunction of the growth hormone pathway in the underlying pathology of cardiac issues in this context.

Overall, the combination of calorie-dense diets and cART regimens promoted myocardial fibrosis, which can disrupt normal electrical conduction.

 How Tesamorelin works (background)

Tesamorelin is a synthetic peptide that stimulates the release of growth hormone (GH), which plays a crucial role in metabolic processes, including fat metabolism and muscle growth. By enhancing GH levels, Tesamorelin may help improve body composition and potentially mitigate some of the adverse effects associated with cART, particularly those affecting cardiovascular health. Research indicates that growth hormone signaling is integral to maintaining cardiovascular function, and disruptions in this pathway can lead to increased risks of myocardial fibrosis and other cardiac complications.

 Practical takeaways for researchers

This study underscores the importance of considering dietary factors when evaluating the safety and efficacy of cART regimens. Researchers should explore the implications of Tesamorelin in clinical trials, particularly in populations at risk for cardiovascular complications. Understanding the interactions between dietary composition, antiretroviral therapy, and growth hormone signaling could lead to improved management strategies for individuals living with HIV. For more information on peptide research and applications, visit our research library.

 FAQ

 What is Tesamorelin used for?

Tesamorelin is primarily used to stimulate growth hormone release and is being studied for its potential benefits in improving body composition and mitigating cardiovascular risks in individuals undergoing antiretroviral therapy.

 How does Tesamorelin affect cardiovascular health?

Research suggests that Tesamorelin may prevent adverse cardiac effects associated with certain antiretroviral therapies, potentially reducing the risk of myocardial fibrosis.

 Are there any side effects associated with Tesamorelin?

While Tesamorelin is generally well-tolerated, potential side effects may include injection site reactions and changes in glucose metabolism. Further studies are needed to fully understand its safety profile.

 Source: PubMed · Braz J Med Biol Res · published 2026-01-01.

## Sources

- PubMed · Braz J Med Biol Res: https://pubmed.ncbi.nlm.nih.gov/42018810/